A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT03997968
• Recruitment Status: Recruiting
• First Posted: June 25, 2019
• Last Update Posted: March 9, 2022
• Sponsor: Cyteir Therapeutics, Inc.
• Information provided by (Responsible Party): Cyteir Therapeutics, Inc.

Study Description

Brief Summary:

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.

Condition or disease	Intervention/treatment	Phase
Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcoma; Head and Neck Cancer; DLBCL; Mantle Cell Lymphoma; Follicular Lymphoma; Pancreatic Cancer; CLL; Small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer	Drug: CYT-0851; Drug: CYT-0851 in combination with gemcitabine; Drug: CYT-0851 in combination with capecitabine; Drug: CYT-0851 in combination with rituximab and bendamustine	Phase 1; Phase 2

Detailed Description:

Overexpression of activation-induced cytidine deaminase (AID) or other cytidine deaminases causes high rates of deoxyribonucleic acid (DNA) damage (mutations, double strand DNA breaks, and chromosome rearrangements) in a high number of patients with B-cell malignancies, such as NHL, MM, and CLL, and in a subset of patients with solid tumors, such as non-small cell lung cancer (NSCLC), sarcoma, breast cancer, ovarian cancer, and squamous cell carcinoma of the head and neck. Cancer cells that overexpress AID and other cytidine deaminases rely on RAD51, a protein involved in homologous recombination, to repair the DNA damage caused by cytidine deaminases. Inhibition of RAD51 with CYT-0851 in preclinical models induces cell death, tumor growth delay or tumor regression.

The Phase 1 part of the study will follow an accelerated titration design, which includes enrollment of single patient cohorts until certain criteria are met, followed by a standard 3+3 design. This design will allow for identification of a recommended phase 2 dose (RP2D) level while dosing the least number of patients as possible at potentially sub-therapeutic doses. Upon identification of the RP2D in the monotherapy, the study will open to three combination treatment arms to identify the RP2D in combination with rituximab and bendamustine in Non-Hodgkin Lymphoma and capecitabine or gemcitabine for solid tumors. In the Phase 2 part of the study, preliminary efficacy will be evaluated in 8 expansion cohorts (total n = 92-220), using a Simon two-stage design. The RP2D will be selected based on the MTD, the safety profile, PK, and available pharmacodynamics data generated from all subjects in Phase 1.

In both Phase 1 and Phase 2, patients will be treated in continuous 21-day or 28-day cycles and all patients will be assessed for response every 2 cycles. Treatment will be terminated if the patient progresses, cannot tolerate treatment, or withdraws consent from active therapy. Patients will undergo a safety evaluation approximately 1 month (28-35 days) after the last dose. Patients will be followed for response until progression is documented.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 320 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
• Actual Study Start Date: October 9, 2019
• Estimated Primary Completion Date: February 2023
• Estimated Study Completion Date: December 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: CYT-0851 dose escalation; Part A: CYT-0851 administered orally in rising doses QD or BID for 28 day cycles	Drug: CYT-0851; Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
Experimental: CYT-0851 dose expansion; Part B: CYT-0851 administered orally at the selected Phase 2 dose for 28 day cycles	Drug: CYT-0851; Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
Experimental: CYT-0851 and rituximab and bendamustine; Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab on Day 1 and bendamustine on Days 1 and 2 of each 28 day cycle	Drug: CYT-0851; Part A and B: Daily oral doses of CYT-0851 for 28 day cycles; Drug: CYT-0851 in combination with rituximab and bendamustine; Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
Experimental: CYT-0851 and gemcitabine; Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine on Day 1, 8 and 15 of each 28 day cycle	Drug: CYT-0851; Part A and B: Daily oral doses of CYT-0851 for 28 day cycles; Drug: CYT-0851 in combination with gemcitabine; Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
Experimental: CYT-0851 and capecitabine; Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine on Days to 14 of each 21 day cycle	Drug: CYT-0851; Part A and B: Daily oral doses of CYT-0851 for 28 day cycles; Drug: CYT-0851 in combination with capecitabine; Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine

Outcome Measures

Primary Outcome Measures :

1. Part A: Incidence of dose limiting toxicity [ Time Frame: 28 Days ]
   Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose
2. Part B: Objective response rate [ Time Frame: 24 Weeks ]
   clinical benefit as determined by investigator assessments of tumor response
3. Part C: Incidence of dose limiting toxicity [ Time Frame: 28 Days ]
   Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose in combination with rituximab and bendamustine
4. Part D: Incidence of dose limiting toxicity [ Time Frame: 28 Days ]
   Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose in combination with gemcitabine
5. Part E: Incidence of dose limiting toxicity [ Time Frame: 21 Days ]
   Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose in combination with capecitabine

Secondary Outcome Measures :

1. Part A: Incidence of adverse events and other safety measures [ Time Frame: 28 Days ]

   incidence of adverse events changes in laboratory parameters, vital signs and ECGs

   • Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events

2. Part C: Incidence of adverse events and other safety measures [ Time Frame: 28 Days ]

   incidence of adverse events changes in laboratory parameters, vital signs and ECGs

   • Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events

3. Part D: Incidence of adverse events and other safety measures [ Time Frame: 28 Days ]

   incidence of adverse events changes in laboratory parameters, vital signs and ECGs

   • Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events

4. Part E: Incidence of adverse events and other safety measures [ Time Frame: 21 Days ]

   incidence of adverse events changes in laboratory parameters, vital signs and ECGs

   • Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events

5. Part A: Assessment of pharmacokinetic parameters [ Time Frame: Phase 1: 12 months ]
   Summarize PK parameters including Cmax, AUC and tmax
6. Part C: Assessment of pharmacokinetic parameters [ Time Frame: Phase 1: 12 months ]
   Summarize PK parameters including Cmax, AUC and tmax
7. Part D: Assessment of pharmacokinetic parameters [ Time Frame: Phase 1: 12 months ]
   Summarize PK parameters including Cmax, AUC and tmax
8. Part E: Assessment of pharmacokinetic parameters [ Time Frame: Phase 1: 12 months ]
   Summarize PK parameters including Cmax, AUC and tmax
9. Part B: Assessment of pharmacokinetic parameters [ Time Frame: Phase 1: 12 months ]
   Summarize PK parameters including Cmax, AUC and tmax
10. Part A: Objective response rate [ Time Frame: 24 months ]
    clinical activity as assessed by investigator assessment of objective response and duration of response
11. Part C: Objective response rate [ Time Frame: 24 months ]
    clinical activity as assessed by investigator assessment of objective response and duration of response
12. Part D: Objective response rate [ Time Frame: 24 months ]
    clinical activity as assessed by investigator assessment of objective response and duration of response
13. Part E: Objective response rate [ Time Frame: 24 months ]
    clinical activity as assessed by investigator assessment of objective response and duration of response
14. Part B: Anti-tumor activity and by DOR [ Time Frame: 24 months ]
    Antitumor activity as assessed by duration of response
15. Part B: Anti-tumor activity by PFS [ Time Frame: 24 months ]
    Antitumor activity as assessed by progression free survival
16. Part B: Anti-tumor activity by DCR [ Time Frame: 24 months ]
    Antitumor activity as assessed by disease control rate
17. Part B: Anti-tumor activity by OS [ Time Frame: 24 months ]
    Antitumor activity as assessed by overall survival
18. Part B: Safety assessment [ Time Frame: 24 months ]
    Safety as determined by incidence of AEs and SAEs and changes in laboratory, vitals and ECG findings

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key Phase 1 Inclusion Criteria

1. Male or female ≥18 years of age at time of informed consent.

   1. Female subjects of childbearing potential must be non-lactating, not pregnant as confirmed by a negative serum pregnancy test at most 30 days before enrollment and within 72 hours before the first administration of CYT-0851
   2. Female subjects of childbearing potential must not donate ova during the study and for at least 90 days after the last dose of study drug and must agree to continue using an effective method of contraception during the screening period to first study drug administration until 90 days after the last dose of study drug
   3. Male subjects who have not had a vasectomy must agree to use an effective method of contraception during the study and until 90 days after the last dose of the study drug, and to not donate sperm during the study and for at least 90 days after the last dose of study drug
2. ECOG Performance Status of 0-1
3. Measurable disease defined by disease-specific response criteria

4. Histologically-proven B cell malignancies, meeting the following criteria:

   1. Relapsed, refractory B-cell non-Hodgkin lymphoma requiring therapy, after at least two prior therapies, and if transplanted, then at least 3-month post autologous stem cell transplant and if CART-treated, then evidence of progression no sooner than 3 months post CART treatment, or
   2. Relapsed, refractory chronic lymphocytic leukemia requiring therapy after at least two prior therapies, including BTK and BCL-2 inhibitor therapy (unless ineligible for such therapy), or
   3. For multiple myeloma, relapsed or progressive on or after treatment with at least three prior therapies that included a proteasome inhibitor, an imide, daratumumab, and if transplant eligible, a bone marrow transplant (unless unfit for transplant), or

5. Histologically-proven solid tumor meeting the following criteria:

   1. Patients must have failed, refused, or not be eligible for further standard therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies, as appropriate) expected to provide clinical benefit, and meeting the following criteria
   2. Metastatic breast cancer (including ER/PR positive or negative, Her-2 positive and negative, triple negative), treated with at least 1 prior therapy for metastatic disease, or
   3. Recurrent squamous cell carcinoma of the head and neck (HNSCC) (dose escalation) or human papilloma virus positive (HPV+) HNSCC (dose-escalation and backfill), treated with at least 1 prior therapy, or
   4. Ovarian cancer, progressive after treatment with at least prior platinum-based chemotherapy, and therapy with a PARP inhibitor or
   5. Soft tissue sarcoma, treated with at least one line of prior systemic therapy, or
   6. Recurrent metastatic or locally advanced pancreatic cancer after first line chemotherapy (backfill patients only) or

   7. Histologically-proven advanced small-cell lung cancer (SCLC) (backfill patients only).

      1. Patients with mixed histology are not allowed
      2. Prior treatment with platinum containing chemotherapy regimen with no evidence of progression within 90 days of last dose of platinum agent and anti-PD-(L)1 unless contraindicated
      3. At least 1 prior line of chemotherapy, but no more than 3 prior lines of therapy
6. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure
7. Willing and able to comply with the requirements of the study protocol
8. Site of disease amenable to a biopsy and willing to undergo biopsy required for backfill, or for dose-escalation if considered unsafe (approval to participate in the study required by the Medical Monitor) provide an archival sample ≤ 12 months old

Key Phase 2 Inclusion Criteria

1. Male or female ≥18 years of age at time of informed consent.

   1. Female subjects of childbearing potential must be non-lactating, not pregnant as confirmed by a negative serum pregnancy test at most 30 days before enrollment and within 72 hours before the first administration of CYT-0851
   2. Female subjects of childbearing potential must not donate ova during the study and for at least 90 days after the last dose of study drug and must agree to continue using, an effective method of contraception during the screening period to first study drug administration until 90 days after the last dose of study drug
   3. Male subjects who have not had a vasectomy must agree to use an effective method of contraception during the study and until 90 days after the last dose of the study drug, and to not donate sperm during the study and for at least 90 days after the last dose of study drug
2. ECOG Performance Status of 0-1
3. Measurable disease defined by disease-specific response criteria
4. Site of disease amenable to a biopsy and willing to undergo a biopsy for the determination of biomarker status, or, if considered unsafe (approval to participate in the study required by the Medical Monitor), archival sample ≤ 12 months old for determination of biomarker status.
5. Biomarker positive on recent biopsy or bone marrow sample if required for the specific cohort.

6. Histologically-proven B cell malignancies, meeting the following criteria:

   1. DLBCL Cohort

      1. Histologically-documented DLBCL or double hit lymphoma (B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma with BCL2 and MYC translocations (WHO Classification)
      2. Progressing on or after treatment with at least two prior lines of therapy, including R-CHOP or equivalent first line therapy
      3. If transplanted, then at least 3-month post autologous stem cell transplant
      4. If CART-treated, then evidence of progression no sooner than 3 months post CART treatment

   2. MCL Cohort

      1. Histologically-documented MCL
      2. Any stage at diagnosis
      3. Progressing on or after treatment with at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor, after a 14-day washout period
   3. Multiple Myeloma Cohort 1) Relapsed or progressing after treatment with at least 3 prior therapies that include a proteasome inhibitor, an Immunomodulatory imide drug (IMiD), daratumumab, and, if transplant eligible, a bone marrow transplant (unless unfit for transplant)

7. Or Histologically-proven solid tumors meeting the following criterial

   1. Patients must have failed, refused, or not be eligible for further standard therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies, as appropriate) expected to provide clinical benefit, and meeting the following criteria

   2. Triple Negative Breast Cancer Cohort

      1. Histologically-documented triple negative breast cancer, ER/PR negative (defined as <10% of cells expressing hormonal receptors via immunohistochemistry (IHC) analysis), and HER2-negative, defined as either of the following by local laboratory assessment:

         • In situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 < 2.0 or single probe average HER2 gene copy number < 4 signals/cell), or
         • IHC 0 or IHC 1+
      2. At least 1 prior line of chemotherapy, but no more than 5 prior lines of chemotherapy

   3. Ovarian Cancer Cohort

      1. Histologically-proven metastatic epithelial ovarian cancer
      2. Prior treatment with a platinum containing chemotherapy regimen
      3. Prior treatment with PARP inhibitor, and, unless in adjuvant setting, responsive to PARP inhibitor, with progression on or following PARP inhibitor treatment
      4. At least 1 prior line of therapy, but no more than 5 prior lines of chemotherapy
   4. Pancreatic Cancer Cohort 1) Histologically-proven metastatic or locally advanced pancreatic cancer 2) At least 1 prior line of chemotherapy but no more than 4 prior lines of systemic therapy

   5. Soft Tissue Sarcoma Cohort

      1. Histologically-proven advanced soft-tissue sarcoma excluding all types of adipocytic sarcoma and GIST
      2. At least 1 prior line of systemic therapy (unless no standard of care exists), but no more than 5 prior lines of systemic therapy

8. Follicular Lymphoma Cohort

   1. Histologically-documented follicular lymphoma
   2. Relapsed, refractory follicular lymphoma requiring therapy, after at least two prior therapies, and if CART-treated, then evidence of progression no sooner than 3 months post CART treatment
9. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure
10. Willing and able to comply with the requirements of the study protocol

Key Exclusion Criteria

1. Medical Conditions

   1. Known history of HIV
   2. Known history of viral hepatitis B unless HBV viral load is below the limit of quantification and off viral suppressive therapy
   3. Know history of hepatitis C unless antiviral treatment with curative intent completed and HCV viral load is below the limit of quantification.
   4. Myocardial infarction or stroke within 6 months
   5. Uncontrolled hypertension (systolic blood pressure (SBP) > 160 or diastolic blood pressure (DBP) >100 on maximal medical therapy)
   6. History of interstitial pulmonary disease
   7. Unresolved pneumonitis
   8. Grade ≥ 3 neuropathy
   9. Known active central nervous system (CNS) metastases. Subjects with previously treated CNS metastases may participate as long as clinically and radiologically stable for at least 4 weeks after treatment, have no evidence of new or enlarging lesions and are off steroids and asymptomatic for 28 days prior to dosing with study medication
   10. Known history of meningeal involvement or meningeal carcinomatosis
   11. Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 2 weeks prior to screening visit
   12. Presence of clinically significant cataracts
   13. Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancy that is in remission or stable and for which patients have not been on active anti-cancer therapy for 2 years
   14. Pregnant or lactating. If β-HCG is elevated, eligible if ultrasound confirms absence of a pregnancy.
   15. Dementia or significantly altered metal status

2. Prior/Concomitant Therapy

   a. Prior allogeneic stem cell transplant b. On systemic antibiotic, antifungal or anti-viral therapy c. White blood cell (WBC) growth factors administered within 14 days of screening visit d. Cancer therapy within 14 days prior to treatment with study drug e. On narrow therapeutic index medications (see Section 7.6.1 for list of drugs) that are sensitive substrates of CYP3A, P-gp or BCRP (or caution is warranted with approval by the Sponsor).

   f. On any drug known to prolong QTc interval (eg, certain antiarrhythmic, antimicrobials) that cannot be discontinued or interrupted 72 hours before the Day 1 dose through Day 2, and 72 hours before the Day 15 dose until Day 16 (BID dosing) or the Day 22 dose until Day 23 (QD dosing), in Cycle 1 (see Section 7.6.1 for a list of drugs).

   g. On systemic corticosteroid treatment for non-tumor indication at a daily dose equivalent to >10mg of Prednisone

3. Prior/Concurrent Clinical Study Experience

   a. Participation in another clinical trial (unless in the observation phase, or an observational study), or exposure to any investigational agent within 14 days prior to treatment with study drug

4. Laboratory assessments

   1. Complete blood count (CBC):

      Monotherapy and Chemotherapy Combinations 1 and 2:

      1. ANC < 1.0 × 10^9/L
      2. PLT < 75 × 10^9/L

      3. Hgb < 9.0 g/dL

         Chemotherapy Combination Group 3:

      1) ANC < 1.5 × 10^9/L 2) PLT < 100 × 10^9/L 3) Hgb < 9.0 g/dL

      Monotherapy and Chemotherapy Combination Groups 1 and 2:

   2. Calculated Creatinine clearance (Cockcroft-Gault) < 40 mL/min

Chemotherapy Combination Group 3:

b. Calculated Creatinine clearance (Cockcroft-Gault) < 50 mL/min c. Hepatic function

1. AST > 2.0 × ULN

2. ALT > 2.0 × ULN d. Total bilirubin > 1.5 x ULN e. Albumin < 2.8 g/dL 5. ECG Exclusion a. Screening QTc interval > 450 milliseconds for males and QTc > 470 ms for females (corrected by Fridericia) 6. Other Exclusions

   1. Unwilling or unable to make all planned study visits
   2. Unwilling or unable to provide a recent biopsy or bone marrow sample prior to enrollment and during study; Note: certain exceptions may be permitted allowing archival specimens prior to treatment or for subjects where a specimen is not required for biomarker positive testing (see Sections 6.1.9.1 and 6.2.8)
   3. Significant medical diseases or conditions, as assessed by the Investigators and Cyteir that would substantially increase the risk-benefit ratio of participating in the study. This includes but is not limited to acute myocardial infarction, arterial thrombosis, significant gastrointestinal bleed, or unstable angina within the last 6 months uncontrolled diabetes mellitus, current active infections, severely immunocompromised state, and congestive heart failure New York Heart Association (NYHA) Class III-IV, left ventricular ejection fraction (LVEF) < 40% d: Chemotherapy Combination Group 3 only: known history of dhydropyrimidine dehydrogenase deficiency

Contacts and Locations

Contacts

Contact: Judson Englert, MD; 857-285-4140; clinicaltrials@cyteir.com

Contact: Susan Doleman; 857-285-4140; clinicaloperations@cyteir.com

Locations

United States, Arizona

Mayo Clinic; Recruiting

Scottsdale, Arizona, United States, 85259

Contact: Clinical Trials Referral Office 855-776-0015

Principal Investigator: Mahesh Seetharam, MD

United States, California

University of California San Francisco; Recruiting

San Francisco, California, United States, 94158

Contact: Lauren Wilch 415-353-3642 Lauren.Wilch@ucsf.edu

Principal Investigator: Pamela Munster, MD

Stanford Comprehensive Cancer Center; Recruiting

Stanford, California, United States, 94305

Contact: Mariel Rojas 650-723-0530 mlrojas@stanford.edu

Principal Investigator: Ranjana Advani, MD

United States, Colorado

Sarah Cannon Research Institute at HealthONE; Recruiting

Denver, Colorado, United States, 80218

Contact: Susan Hall 720-754-2610 Susan.Hall3@sarahcannon.com

Principal Investigator: Shiraj Sen, MD

United States, Florida

Mayo Clinic; Recruiting

Jacksonville, Florida, United States, 32224

Contact: Clinical Trials Referral Office 855-776-0015

Principal Investigator: Han Win Tun, MD

Florida Cancer Specialists and Research Institute; Recruiting

Sarasota, Florida, United States, 34232

Contact: Karolyn Simpson, RN 941-377-9993 KaSimpson@flcancer.com

Principal Investigator: Manesh R Patel, MD

United States, Massachusetts

Massachusetts General Hospital; Recruiting

Boston, Massachusetts, United States, 02114

Contact: Dejan Juric, MD 617-724-4000 djuric@partners.org

Principal Investigator: Dejan Juric, MD

Dana Farber Cancer Institute; Recruiting

Boston, Massachusetts, United States, 02115

Contact 877-338-7425

Principal Investigator: Geoffrey I. Shapiro, MD

United States, Michigan

University of Michigan; Recruiting

Ann Arbor, Michigan, United States, 48109

Contact: Monica Burness, MD 734-232-0759 mburness@med.umich.edu

Principal Investigator: Monica Burness, MD

United States, Minnesota

Mayo Clinic; Recruiting

Rochester, Minnesota, United States, 55905

Contact: Clinical Trials Referral Office 855-776-0015

Principal Investigator: Grzegorz S Nowakowski, MD

United States, New Jersey

John Theurer Cancer Center at HUMC; Recruiting

Hackensack, New Jersey, United States, 07601

Contact: Chelsea McCabe 551-996-4725 chelsea.mccabe@hackensackmeridian.org

Principal Investigator: Martin Gutierrez, MD

United States, New York

NYU Langone Health; Recruiting

New York, New York, United States, 10016

Contact: Nina Beri, MD 212-731-5770 Nina.Beri@nyulangone.org

Principal Investigator: Nina Beri, MD

United States, Oklahoma

Oklahoma University-Stephenson Cancer Center; Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contact 405-271-8778 PhaseI-Referrals@ouhsc.edu

Principal Investigator: Kathleen Moore, MD

United States, Pennsylvania

Thomas Jefferson University, Sidney Kimmel Cancer Center; Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contact: Dennis Stone 215-955-6407 Dennis.Stone@Jefferson.edu

Principal Investigator: Neil Palmisiano, MD

United States, Tennessee

Sarah Cannon Research Institute at Tennessee Oncology; Recruiting

Nashville, Tennessee, United States, 37203

Contact: Davinia McComb, RN, OCN 615-815-9963

Principal Investigator: Johanna C Bendell, MD

United States, Texas

The University of Texas MD Anderson Cancer Center; Recruiting

Houston, Texas, United States, 77030

Contact: Sarah Travasos 713-563-4431 sktravasos@mdanderson.org

Principal Investigator: Timothy A Yap, MD, PhD

United States, Washington

University of Washington Seattle Cancer Center; Recruiting

Seattle, Washington, United States, 98109

Contact: Harini Ramachandran 206-606-6448 harinir@seattlecca.org

Principal Investigator: Ryan Lynch, MD

United States, Wisconsin

Medical College of Wisconsin; Recruiting

Milwaukee, Wisconsin, United States, 53226

Contact: Michael Jacklin 414-804-8839 mjacklin@mcw.com

Principal Investigator: Mehdi Hamadani, MD

Sponsors and Collaborators

Cyteir Therapeutics, Inc.

Investigators

• Study Director: Judson Englert, MD; Cyteir Therapeutics

More Information

Publications of Results:

Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, Rüter J, Mills KD. Attenuating homologous recombination stimulates an AID-induced antileukemic effect. J Exp Med. 2013 May 6;210(5):1021-33.

• Responsible Party: Cyteir Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT03997968
• Other Study ID Numbers: CYT-0851-01
• First Posted: June 25, 2019
• Last Update Posted: March 9, 2022
• Last Verified: December 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Cyteir Therapeutics, Inc.:

Oral RAD51-inhibitor; refractory; B-cell; solid tumor; DNA Damage Repair inhibitor; cancer

Additional relevant MeSH terms:

Lymphoma; Breast Neoplasms; Multiple Myeloma; Neoplasms; Sarcoma; Lymphoma, Mantle-Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplasms by Site; Breast Diseases; Skin Diseases; Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders; Lymphoma, Non-Hodgkin; Neoplasms, Connective and Soft Tissue